Alsalim W, et al. - The intention herein was to investigate the effects of dipeptidyl peptidase (DPP)-4 inhibition and sodium-glucose co-transporter 2 (SGLT-2) inhibition on the glucagon levels in individuals with type 2 diabetes (T2D). As per the outcomes, treatment with DPP-4 inhibition with vildagliptin led to 15% lower fasting and postprandial glucagon levels compared to SGLT-2 inhibition with dapagliflozin. Additionally, DPP-4 inhibition induced a more rapid insulin secretion and higher levels of intact incretin hormones, which, in turn, gave rise to stronger feedback inhibition of incretin hormone secretion compared to SGLT-2 inhibition.